- Home
- PCYO vs GALT Comparison
PCYO vs GALT Comparison
Compare PCYO & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- GALT
- Stock Information
- Founded
- PCYO 1976
- GALT 2000
- Country
- PCYO United States
- GALT United States
- Employees
- PCYO N/A
- GALT N/A
- Industry
- PCYO Water Supply
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- PCYO Utilities
- GALT Health Care
- Exchange
- PCYO Nasdaq
- GALT Nasdaq
- Market Cap
- PCYO 267.7M
- GALT 232.3M
- IPO Year
- PCYO N/A
- GALT N/A
- Fundamental
- Price
- PCYO $11.22
- GALT $5.67
- Analyst Decision
- PCYO
- GALT Strong Buy
- Analyst Count
- PCYO 0
- GALT 3
- Target Price
- PCYO N/A
- GALT $6.00
- AVG Volume (30 Days)
- PCYO 51.3K
- GALT 384.3K
- Earning Date
- PCYO 11-12-2025
- GALT 11-14-2025
- Dividend Yield
- PCYO N/A
- GALT N/A
- EPS Growth
- PCYO 12.50
- GALT N/A
- EPS
- PCYO 0.54
- GALT N/A
- Revenue
- PCYO $26,087,000.00
- GALT N/A
- Revenue This Year
- PCYO N/A
- GALT N/A
- Revenue Next Year
- PCYO N/A
- GALT N/A
- P/E Ratio
- PCYO $20.39
- GALT N/A
- Revenue Growth
- PCYO N/A
- GALT N/A
- 52 Week Low
- PCYO $9.65
- GALT $0.73
- 52 Week High
- PCYO $14.63
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- PCYO 60.70
- GALT 54.41
- Support Level
- PCYO $10.73
- GALT $5.23
- Resistance Level
- PCYO $11.22
- GALT $6.32
- Average True Range (ATR)
- PCYO 0.23
- GALT 0.55
- MACD
- PCYO 0.01
- GALT -0.04
- Stochastic Oscillator
- PCYO 68.59
- GALT 50.00
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.